The Inflation Reduction Act: Hope for Prescription Drug Prices in the USA Lindsay Allen Editorial 06 October 2023 Pages: 5 - 7
Modelling Informal Carers’ Health-Related Quality of Life: Challenges for Economic Evaluation Becky PenningtonHareth Al-Janabi Current Opinion Open access 10 November 2023 Pages: 9 - 16
A Systematic Review of the World’s Largest Government Sponsored Health Insurance Scheme for 500 Million Beneficiaries in India: Pradhan Mantri Jan Arogya Yojana AashimaRajesh Sharma Systematic Review 06 October 2023 Pages: 17 - 32
Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review Yan LiPingyu ChenHongchao Li Systematic Review 29 October 2023 Pages: 33 - 48
Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom Max KindredZahratu ShabrinaNeily Zakiyah Original Research Article Open access 10 November 2023 Pages: 49 - 60
Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older Shoroq M. AltawalbehAngela R. WateskaKenneth J. Smith Original Research Article 15 November 2023 Pages: 61 - 71
Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy Constanza VargasRebecca AddoStephen Goodall Original Research Article 11 November 2023 Pages: 73 - 84
Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA Rui LiPengyi LuLei Zhang Original Research Article 01 November 2023 Pages: 85 - 95
VOLY: The Monetary Value of a Life-Year at the End of Patients’ Lives Elizabeta RibarićIsmar VelićAna Bobinac Original Research Article 04 October 2023 Pages: 97 - 106
Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia Martin VuKoen DegelingMaarten J. IJzerman Original Research Article Open access 22 August 2023 Pages: 107 - 122
Comment on: “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022” Sieta T. de VriesNoral Huda S. Al-MugoterPeter G. M. Mol Research Letter 16 November 2023 Pages: 123 - 124
Comment on: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?” Afschin Gandjour Letter to the Editor Open access 02 December 2023 Pages: 125 - 126
Authors’ Reply to Gandjour: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?” Melanie BüssgenTom Stargardt Letter to the Editor Open access 02 December 2023 Pages: 127 - 128